Krystal Biotech, Inc. $KRYS Stake Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 4.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 38,697 shares of the company’s stock after acquiring an additional 1,760 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.13% of Krystal Biotech worth $14,383,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Handelsbanken Fonder AB lifted its position in shares of Krystal Biotech by 58.4% during the 4th quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock valued at $26,084,000 after acquiring an additional 39,000 shares during the last quarter. Fisher Asset Management LLC acquired a new position in shares of Krystal Biotech in the 4th quarter worth $933,000. Principal Financial Group Inc. lifted its holdings in shares of Krystal Biotech by 15.6% during the fourth quarter. Principal Financial Group Inc. now owns 165,074 shares of the company’s stock valued at $40,697,000 after purchasing an additional 22,231 shares during the last quarter. William Blair Investment Management LLC boosted its position in shares of Krystal Biotech by 152.1% in the 4th quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock valued at $92,783,000 after purchasing an additional 227,038 shares during the period. Finally, Biondo Investment Advisors LLC boosted its position in shares of Krystal Biotech by 31.3% in the 4th quarter. Biondo Investment Advisors LLC now owns 68,130 shares of the company’s stock valued at $16,797,000 after purchasing an additional 16,245 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $358.24 on Friday. Krystal Biotech, Inc. has a fifty-two week low of $136.73 and a fifty-two week high of $382.54. The stock’s 50-day moving average is $349.81 and its two-hundred day moving average is $307.38. The stock has a market cap of $10.60 billion, a PE ratio of 44.89 and a beta of 0.54.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. The business had revenue of $119.22 million during the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. On average, equities research analysts anticipate that Krystal Biotech, Inc. will post 7.48 earnings per share for the current year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the sale, the insider owned 1,302,145 shares in the company, valued at $467,886,741.40. This represents a 1.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino Rossi sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the sale, the director directly owned 50,000 shares of the company’s stock, valued at $16,456,000. This trade represents a 33.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 51,000 shares of company stock worth $17,558,270 in the last quarter. 13.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

KRYS has been the topic of several recent analyst reports. Jefferies Financial Group restated a “buy” rating and set a $474.00 price objective on shares of Krystal Biotech in a report on Monday, July 13th. Citigroup lifted their target price on shares of Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Bank of America boosted their price target on shares of Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Monday, August 3rd. Finally, HC Wainwright raised their price objective on shares of Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research note on Tuesday, June 16th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $365.40.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.